EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma

Alessandro Cucchetti, Edoardo G. Giannini, Cristina Mosconi, Maria Corina Plaz Torres, Giulia Pieri, Fabio Farinati, Gian Ludovico Rapaccini, Maria Di Marco, Eugenio Caturelli, Rodolfo Sacco, Giuseppe Cabibbo, Claudia Campani und 15 weitere

Liver Cancer International · 2021

DOI: 10.1002/lci2.33 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver Cancer International, 2021. Verfasst von Alessandro Cucchetti und 26 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims The Pre‐TACE‐Predict model was devised to assess prognosis of patients treated with trans‐arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). However, before entering clinical practice, a model should demonstrate that it performs a useful role.

Methods

We performed an independent external validation of the Pre‐TACE model in a cohort that differs in setting and time period from the one that generated the original model. Data from 826 patients treated with TACE for naïve HCC (2008‐2018) were used to assess calibration and discrimination of the Pre‐TACE‐Predict model.

Results

The four risk‐categories identified by the Pre‐TACE‐Predict model had gradient monotonicity, with median survivals of 52.0, 36.2, 29.9, and 14.1 months respectively. However, predicted survivals systematically underestimated observed survivals ( R 2 : 0.667). A recalibration was adopted maintaining fixed the prognostic index and modifying the baseline survival function. This resulted in an almost perfect calibration ( R 2 : 0.995) in all the four risk categories. Cox regressions showed that aetiology and macrovascular invasion, included in the Pre‐TACE‐Predict model, had no prognostic impact in the present study population, and that coefficients for tumour size and multiplicity were overestimated. The c ‐index was similar to that of the m‐HAP‐III, but higher than those of HAP, m‐HAP‐II and the six‐and‐twelve models.

Conclusions

The recalibration of Pre‐TACE‐Predict model improved the estimation of survival probabilities of HCC patients treated with TACE. The highest discriminatory ability of the Pre‐TACE‐model in comparison to other available models, together with risk stratification and recalibration, makes it the best prognostic tool currently available for these patients.

Zitieren

APA

Cucchetti, A., Giannini, E. G., Mosconi, C., Torres, M. C. P., Pieri, G., Farinati, F., Rapaccini, G. L., Marco, M. D., Caturelli, E., Sacco, R., Cabibbo, G., Campani, C., Mega, A., Guarino, M., Gasbarrini, A., Svegliati‐Baroni, G., Foschi, F. G., Missale, G., Masotto, A., …, & Trevisani, F. (2021). Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma. Liver Cancer International. https://doi.org/10.1002/lci2.33

Vancouver

Cucchetti A, Giannini EG, Mosconi C, Torres MCP, Pieri G, Farinati F, et al. Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma. Liver Cancer International. 2021. doi:10.1002/lci2.33

BibTeX
@article{Cucchetti2021,
  author = {Cucchetti, Alessandro and Giannini, Edoardo G. and Mosconi, Cristina and Torres, Maria Corina Plaz and Pieri, Giulia and Farinati, Fabio and Rapaccini, Gian Ludovico and Marco, Maria Di and Caturelli, Eugenio and Sacco, Rodolfo and Cabibbo, Giuseppe and Campani, Claudia and Mega, Andrea and Guarino, Maria and Gasbarrini, Antonio and Svegliati‐Baroni, Gianluca and Foschi, Francesco Giuseppe and Missale, Gabriele and Masotto, Alberto and Nardone, Gerardo and Raimondo, Giovanni and Vidili, Gianpaolo and Brunetto, Maurizia Rossana and Sansone, Vito and Zoli, Marco and Azzaroli, Francesco and Trevisani, Franco},
  title = {Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma},
  journal = {Liver Cancer International},
  year = {2021},
  doi = {10.1002/lci2.33}
}
Kostenlos starten →